ALSE — Alseres Pharmaceuticals Share Price
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -178.12% |
Financial Summary
Year End 31st Dec | Unit | 2009 | 2010 | 2011 | 2012 | 2013 | 2014E | 2015E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | 0.53 | 0.47 | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). The Company's lead product candidate is Altropane. The Company's Altropane product is a molecular imaging agent used to diagnose Parkinson's disease and dementia. The Company is focused on entering into partnerships to ensure development and commercialization of its product.
Directors
- Last Annual
- December 31st, 2013
- Last Interim
- June 30th, 2014
- Incorporated
- May 18th, 1972
- Public Since
- January 3rd, 1989
- No. of Employees
- 3
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 6,127.14
- Address
- 275 Grove Street, Suite 2-400, AUBURNDALE, 02466
- Web
- http://www.alseres.com/
- Phone
- +1 6174193289
- Auditors
- McGladrey LLP
Upcoming Events for ALSE
Similar to ALSE
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 19:12 UTC, shares in Alseres Pharmaceuticals are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Alseres Pharmaceuticals last closed at $0.01 and the price had moved by -50% over the past 365 days. In terms of relative price strength the Alseres Pharmaceuticals share price has underperformed the S&P500 Index by -62.15% over the past year.
There is no consensus recommendation for this security.
Find out moreAlseres Pharmaceuticals does not currently pay a dividend.
Alseres Pharmaceuticals does not currently pay a dividend.
Alseres Pharmaceuticals does not currently pay a dividend.
To buy shares in Alseres Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Alseres Pharmaceuticals had a market capitalisation of .
Here are the trading details for Alseres Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ALSE
Based on an overall assessment of its quality, value and momentum Alseres Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alseres Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -55.88%.
As of the last closing price of $0.01, shares in Alseres Pharmaceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alseres Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alseres Pharmaceuticals' management team is headed by:
- Peter Savas - CHM
- Kenneth Rice - CFO
- William Guinness - IND
- Michael Mullen - IND